Psilocybin vs. Ketamine for Depression: Which Is Better?
Two psychedelic-adjacent compounds have emerged as the most promising new treatments for depression: ketamine (FDA-approved as Spravato nasal spray) and psilocybin (in Phase 3 trials). Both work when SSRIs fail, but they work differently and suit different patients.
Mechanism Comparison
Ketamine blocks NMDA glutamate receptors, rapidly increasing synaptic glutamate and triggering BDNF release. Effects begin within hours. Psilocybin activates 5-HT2A serotonin receptors, disrupting default mode network hyperconnectivity and triggering neuroplasticity. Effects develop over days to weeks after a session.
Efficacy Comparison
Both show approximately 50–70% response rates in treatment-resistant depression. Ketamine's advantage is speed: significant improvement often within 24 hours. Psilocybin's advantage is durability: effects from a single session can persist 3–12 months. Ketamine typically requires maintenance infusions every 2–4 weeks to sustain effects; psilocybin does not.
Cost Comparison
Ketamine infusions cost $400–800 per session, and maintenance requires ongoing treatment — potentially $10,000–20,000 per year. Psilocybin therapy (when available through clinical programs) costs $1,000–3,000 per session but requires far fewer sessions. Consumer psilocybin supplements like Shrooomz ($149/bottle) offer a much more accessible option for microdosing protocols.
Who Each Treatment Is Best For
Ketamine is best for acute, severe depression requiring rapid response — suicidal ideation, inability to function. Psilocybin (supervised sessions) is best for treatment-resistant depression where durability matters more than speed. Consumer psilocybin microdosing is best for mild-to-moderate depression, burnout, and anxiety where clinical access isn't available.